- Home
- URGN vs MVF Comparison
URGN vs MVF Comparison
Compare URGN & MVF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- MVF
- Stock Information
- Founded
- URGN 2004
- MVF 1988
- Country
- URGN United States
- MVF United States
- Employees
- URGN N/A
- MVF N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- MVF Investment Bankers/Brokers/Service
- Sector
- URGN Health Care
- MVF Finance
- Exchange
- URGN Nasdaq
- MVF Nasdaq
- Market Cap
- URGN 465.9M
- MVF 465.2M
- IPO Year
- URGN 2017
- MVF N/A
- Fundamental
- Price
- URGN $10.27
- MVF $7.18
- Analyst Decision
- URGN Strong Buy
- MVF
- Analyst Count
- URGN 5
- MVF 0
- Target Price
- URGN $44.50
- MVF N/A
- AVG Volume (30 Days)
- URGN 487.3K
- MVF 162.8K
- Earning Date
- URGN 03-13-2025
- MVF 01-01-0001
- Dividend Yield
- URGN N/A
- MVF 4.11%
- EPS Growth
- URGN N/A
- MVF N/A
- EPS
- URGN N/A
- MVF N/A
- Revenue
- URGN $89,363,000.00
- MVF N/A
- Revenue This Year
- URGN $13.39
- MVF N/A
- Revenue Next Year
- URGN $45.06
- MVF N/A
- P/E Ratio
- URGN N/A
- MVF N/A
- Revenue Growth
- URGN 15.64
- MVF N/A
- 52 Week Low
- URGN $9.78
- MVF $5.85
- 52 Week High
- URGN $20.70
- MVF $7.19
- Technical
- Relative Strength Index (RSI)
- URGN 39.53
- MVF 48.93
- Support Level
- URGN $10.12
- MVF $7.14
- Resistance Level
- URGN $10.96
- MVF $7.26
- Average True Range (ATR)
- URGN 0.57
- MVF 0.08
- MACD
- URGN -0.01
- MVF 0.01
- Stochastic Oscillator
- URGN 24.75
- MVF 77.63
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About MVF Blackrock MuniVest Fund Inc.
Blackrock Munivest Fund Inc is an investment management firm. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The company invests in various sectors such as Health; Transportation; Utilities; Education; Tobacco; Housing and others.